• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Management of antiangiogenic therapy-induced hypertension.抗血管生成治疗所致高血压的管理
Hypertension. 2012 Sep;60(3):607-15. doi: 10.1161/HYPERTENSIONAHA.112.196774. Epub 2012 Jul 30.
2
Sunitinib as adjuvant therapy for renal cell carcinoma.舒尼替尼作为肾细胞癌的辅助治疗
Lancet Oncol. 2016 Nov;17(11):e485. doi: 10.1016/S1470-2045(16)30511-3. Epub 2016 Oct 20.
3
Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.使用苹果酸舒尼替尼治疗的肾细胞癌患者发生肿瘤溶解综合征。
Lancet. 2007 Jun 9;369(9577):1923-4. doi: 10.1016/S0140-6736(07)60903-9.
4
Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.一名接受舒尼替尼治疗转移性肾细胞癌的患者发生主动脉夹层。
Ann Oncol. 2010 Jan;21(1):186-7. doi: 10.1093/annonc/mdp480. Epub 2009 Oct 29.
5
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.舒尼替尼和索拉非尼抗血管生成治疗期间出血性直肠结肠炎急性加重
Ann Oncol. 2008 Nov;19(11):1975. doi: 10.1093/annonc/mdn566. Epub 2008 Aug 22.
6
Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.一名接受舒尼替尼治疗肾细胞癌的患者发生致命性肝衰竭。
Clin Genitourin Cancer. 2013 Mar;11(1):70-2. doi: 10.1016/j.clgc.2012.09.005. Epub 2012 Oct 12.
7
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.辅助舒尼替尼治疗肾切除术后高危肾细胞癌：亚组分析和更新的总生存结果。
Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.
8
[Treatment with sunitinib and hypothyroidism--a case report and overview of literature].[舒尼替尼治疗与甲状腺功能减退——一例病例报告及文献综述]
Klin Onkol. 2009;22(4):176-8.
9
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.动脉高血压以及舒尼替尼、索拉非尼和贝伐单抗在转移性肾细胞癌一线及二线治疗中的临床获益
Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201.
10
Pazopanib outscores sunitinib on tolerability.帕唑帕尼在耐受性方面优于舒尼替尼。
Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

引用本文的文献

1
Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.尼拉帕利和安罗替尼治疗铂耐药卵巢癌患者的不良事件管理：II期多中心ANNIE研究的最新进展
Ther Clin Risk Manag. 2025 Jul 21;21:1135-1147. doi: 10.2147/TCRM.S526755. eCollection 2025.
2
Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.胶质母细胞瘤中抗血管内皮生长因子（VEGF）治疗的出血和缺血风险
Cancer Gene Ther. 2025 May 21. doi: 10.1038/s41417-025-00914-8.
3
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial.苏呋替尼联合特瑞普利单抗治疗初治、PD-L1阳性、晚期或转移性非小细胞肺癌及既往接受过治疗的小细胞肺癌的疗效和安全性：一项开放标签、单臂、多中心、多队列II期试验。
Cancer Immunol Immunother. 2025 Feb 1;74(3):83. doi: 10.1007/s00262-024-03932-x.
4
Reviewing the path to balance: mechanisms and management of hypertension associated with targeting vascular endothelium in cancer therapy.审视平衡之路：癌症治疗中靶向血管内皮相关高血压的机制与管理
Hypertens Res. 2025 Mar;48(3):1034-1047. doi: 10.1038/s41440-024-02086-8. Epub 2025 Jan 16.
5
Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.针对血管内皮生长因子受体抑制剂，识别缓解血管内皮细胞功能障碍和高血压的策略。
Clin Sci (Lond). 2024 Sep 18;138(18):1131-1150. doi: 10.1042/CS20240537.
6
Cardiovascular implications of anti-angiogenic therapeutic agents in cancer patients.抗血管生成治疗药物对癌症患者心血管系统的影响
Am Heart J Plus. 2024 May 23;43:100406. doi: 10.1016/j.ahjo.2024.100406. eCollection 2024 Jul.
7
Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials.癌症患者使用血管内皮生长因子受体（VEGFR）抑制剂（阿昔替尼）治疗时的系统性高血压：一项随机对照试验的荟萃分析和系统评价
Int J Cardiol Heart Vasc. 2024 May 5;52:101415. doi: 10.1016/j.ijcha.2024.101415. eCollection 2024 Jun.
8
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).癌症靶向治疗和免疫治疗心血管毒性的新见解：超越非阻塞性冠状动脉缺血（INOCA）。
Am Heart J Plus. 2024 Mar 1;40:100374. doi: 10.1016/j.ahjo.2024.100374. eCollection 2024 Apr.
9
Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab.病例报告：使用阿替利珠单抗和贝伐单抗成功治疗一名患有多灶性肝细胞癌的血液透析患者。
Front Oncol. 2024 Jan 4;13:1279501. doi: 10.3389/fonc.2023.1279501. eCollection 2023.
10
CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review.CDK4/6抑制剂：乳腺癌治疗中的基础知识、优势及主要弊端，尤其涉及心脏毒性——一篇叙述性综述
Ther Adv Med Oncol. 2023 Oct 11;15:17588359231205848. doi: 10.1177/17588359231205848. eCollection 2023.

本文引用的文献

1
Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.regorafenib 诱导血浆一氧化氮和内皮素-1 的快速和可逆变化。
Am J Hypertens. 2012 Oct;25(10):1118-23. doi: 10.1038/ajh.2012.97. Epub 2012 Jul 12.
2
Suicide and cardiovascular death after a cancer diagnosis.癌症诊断后的自杀和心血管死亡。
N Engl J Med. 2012 Apr 5;366(14):1310-8. doi: 10.1056/NEJMoa1110307.
3
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.舒尼替尼诱导的猪系统性血管收缩是内皮素介导的，不涉及一氧化氮或氧化应激。
Hypertension. 2012 Jan;59(1):151-7. doi: 10.1161/HYPERTENSIONAHA.111.182220. Epub 2011 Nov 28.
4
Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.新型血管生成抑制剂治疗癌症对心血管系统的影响：聚焦于高血压。
Circulation. 2011 Oct 11;124(15):1687-91. doi: 10.1161/CIRCULATIONAHA.110.992230.
5
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.血管内皮生长因子和血管内皮生长因子受体 2 单核苷酸多态性与舒尼替尼治疗转移性透明细胞肾细胞癌患者的高血压和临床结局的关系。
Cancer. 2012 Apr 1;118(7):1946-54. doi: 10.1002/cncr.26491. Epub 2011 Aug 31.
6
The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.血管内皮生长因子受体抑制剂舒尼替尼可引起类似于先兆子痫的综合征，并激活内皮素系统。
Hypertension. 2011 Aug;58(2):295-302. doi: 10.1161/HYPERTENSIONAHA.111.173559. Epub 2011 Jun 13.
7
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.舒张期血压作为固体肿瘤阿昔替尼疗效的生物标志物。
Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29.
8
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.高血压作为舒尼替尼治疗转移性肾细胞癌患者疗效的生物标志物。
J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28.
9
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.受体酪氨酸激酶抑制剂凡德他尼对人体组成型和流动刺激一氧化氮生成的相反作用。
Hypertension. 2011 Jul;58(1):85-92. doi: 10.1161/HYPERTENSIONAHA.110.168120. Epub 2011 Apr 11.
10
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.化疗联合贝伐珠单抗的静脉血栓栓塞事件：随机 II 期和 III 期研究患者的汇总分析。
J Clin Oncol. 2011 May 1;29(13):1757-64. doi: 10.1200/JCO.2010.32.3220. Epub 2011 Mar 21.

Management of antiangiogenic therapy-induced hypertension.

作者信息

de Jesus-Gonzalez Nilka, Robinson Emily, Moslehi Javid, Humphreys Benjamin D

机构信息

Division of Nephrology, Boston Children's Hospital, Boston, MA, USA.

出版信息

Hypertension. 2012 Sep;60(3):607-15. doi: 10.1161/HYPERTENSIONAHA.112.196774. Epub 2012 Jul 30.

DOI:10.1161/HYPERTENSIONAHA.112.196774
PMID:22851729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3421063/
Abstract
摘要